Background: Treatment of T-cell lymphoblastic lymphoma (T-LBL) with CHOP or CHOP-like chemotherapy has resulted in poor long-term outcomes. High-dose chemotherapy followed by ASCT has been applied for this dreaded disease. However, the efficacy is still controversial. T-LBL is considered the nodal/extranodal presentation of acute lymphoblastic leukemia. Favorable results with VPDL chemotherapy have been reported in the setting of adult lymphoblastic leukemia. We, therefore, treated T-LBL patients with modified VPDL chemotherapy and compared the outcomes with those achieved using upfront ASCT. Methods: We retrospectively reviewed the outcomes of 24 T-LBL patients treated either with upfront ASCT (n=11) or VPDL chemotherapy without ASCT (n=13) between January 1996 and October 2005. Results: The median follow-up duration for surviving patients was 17 months (range, 5∼109 months). The two-year event-free survival (EFS) rates were 83.1% in the VPDL group and 27.3% in the upfront ASCT group (P=0.008). The two-year overall survival (OS) rates were 83.9% in the VPDL group and 27.3% in the upfront ASCT group (P=0.006).
INTRODUCTION
Lymphoblastic lymphoma (LBL) is an uncommon malignancy accounting for less than 2% of non-Hodgkin's lymphomas (NHL). 1) About 80%
of LBLs are of T-cell immunophenotype (T-LBL), with the remainder being B cell type (B-LBL). In the World Health Organization classification, LBL is considered a precursor B-cell/ T-cell neoplasm and the nodal/extranodal presentation of acute lymphoblastic leukemia (ALL).
2) Table 2 ). Abbreviations: CODOX-M, cyclophosphamide, doxorubicin, vincristine, cytarabine and methotrexate (iv and intrathecal); CVPD, cyclophosphamide, vincristine, dexamethasone, and doxorubicin; DHAP, cytarabine, cisplatin, and dexamethasone; ESHAP, etoposide, methylprednisolone, cytarabine, and cisplatin; IVAC, ifosfamide, etoposide, cytarabin, and methotrexate (intrathecal); Vanderbilt, cyclophosphamide, etoposide, vincristine, bleomycin, methotrexate, and prednisolone; VPDL, vincristine, prednisolone, daunorubicin, and L-asparaginase.
Treatment with CHOP or CHOP-like chemotherapy protocols has resulted in poor long-term outcomes. [3] [4] [5] [6] Attempts to improve long-term outcomes have resulted in chemotherapy programs that integrate consolidation with stem cell transplantation (SCT). 5, [7] [8] [9] A prospective study comparing chemotherapy alone and upfront autologous SCT (ASCT), however, failed to show better efficacy of ASCT in the treatment of T-LBL. 10) A treatment program using intensive, cyclical chemotherapy using alternating courses of non-crossresistant drugs including L-asparaginase was introduced to treat adult ALL and produced high response rate and prolonged disease-free survival. 11) We applied the regimen, VPDL chemotherapy to treat T-LBL patients and compared the results with the outcome of upfront ASCT.
MATERIALS AND METHODS

Study group
From January 1996 to October 2005, 28 adult patients presented with T-LBL at Asan Medical Center. Four patients who underwent ASCT for relapse of disease were excluded. Follow-up data were collected until April 20, 2007 . Eligibility criteria included age ≥15 years, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3, adequate renal and hepatic functions, and absence of HIV infection.
Diagnosis
Diagnosis was based on morphological and immunohistochemical examination of materials from lymph nodes or bone marrow using routine techniques, all of which were reviewed by a pathologist (JH). Histopathological classification was based on the World Health Organization (WHO) criteria for T-LBL. 2) 
Staging
Clinical, laboratory, and radiological evaluations included physical examination, CT scans of the thorax, abdomen and pelvis, bilateral bone marrow aspiration and biopsy, complete blood cell count with differential, liver and kidney function tests, and serum lactate dehydrogenase (LDH). Patients were staged according to the Ann Arbor staging classification. 12) The age-adjusted International Prognostic Index (IPI) was based on performance status, tumor stage and serum LDH. 13) 
Chemotherapy
From January 1996 to March 2002, patients diagnosed with T-LBL in Asan Medical Center were treated with one of several chemotherapy regimens for aggressive histology lymphoma ( Table 1) . Those who showed no response to initial induction chemotherapy were allowed to receive second-line aggressive chemotherapy. All of those who attained CR or partial remission (PR) underwent ASCT. Patients diagnosed with T-LBL between April 2002 and October 2005 were treated with VPDL chemotherapy after modification from the original regimen without ASCT. Dose of daunorubicin was reduced from 50mg/m 2 to 45mg/m 2 , dose of L-asparaginase was reduced from 6,000units/m 2 to 4,000units/m 2 and VP-16 was substituted for teniposide ( Table 2 ).
11)
ASCT protocols
Two patients were mobilized with cyclophosphamide (4g/m 2 ) plus granulocyte-colony stimulation factor (G-CSF; 10μ/kg/day; Lenograstim, Choongwae Pharma Corp., Seoul, Korea) for stem cell collection and nine were mobilized with on-going chemotherapy plus G-CSF. The minimum collection target was 2×10 6 CD 34 + cells/ kg. All patients received carmustine, etoposide, doxorubicin, and cyclophosphamide (BEAC) as a conditioning regimen. Patients received supportive care according to current protocols at our institution.
Response criteria
Responses to chemotherapy and ASCT were evaluated according to International Workshop to Standardize Response criteria. 14) Routine follow-up imaging analysis was performed every 3 months for the first 2 years after initial treat-ment, every 6 months for the next 3 years, and then yearly or whenever clinically indicated.
Statistical analysis
Overall survival (OS) was calculated from the date of first chemotherapy until death from any cause or until last follow-up for surviving patients. Event-free survival (EFS) was calculated from the date of first chemotherapy until relapse, disease progression, death from any cause or until last follow-up. Duration of CR was defined from the earliest date of complete response to the date of death from any cause, disease progression or relapse, or censored at the date of last contact. Estimated OS, EFS rates and duration of CR were calculated using the product-limit method of Kaplan-Meier and compared using the logrank test. Two-tailed P values of <0.05 were regarded as significant. All calculations were performed using Statistical Package for the Social Sciences (SPSS) version 12.0 (SPSS, Chicago, IL, USA). One patient expired from GVHD after salvage allo-SCT and the other from VOD. Abbreviations: CR, complete response; PR, partial response; PD, progressive disease; NA, not available. 
RESULTS
Patient characteristics
Patient characteristics at presentation are listed in Table 3 . The ASCT and VPDL groups did not differ significantly in age, sex distribution, stage, B symptom status, performance (ECOG), level of LDH, extranodal involvement, mediastinal involvement, bone marrow involvement and age-adjusted IPI.
Response and survival after treatment
Of the 13 patients in the VPDL group, 9 attained CR and 2 attained PR, whereas the other 2 patients showed progressive disease (PD) (P= 0.695). Of the 11 patients in the ASCT group, one who achieved CR after initial chemotherapy sustained CR after ASCT, and additional 5 patients attained CR following ASCT. Of the remaining five patients in this group, two attained PR, two showed PD and one died before assessment (Table 4 ). At a median follow-up of 17 months (range, 5∼109 months), the 2-year OS rate was 83.9% in the VPDL group and 27.3% in the ASCT group, with an overall rate of 61.3% for all of the 24 patients ( Fig. 1, P=0.006) . The 2-year EFS rate was 83.1% in the VPDL group and 27.3% in the ASCT group (Fig. 2, P=0.008) . Median OS and EFS for the ASCT group were 14.4 and 11.7 months, respectively, whereas the median OS and EFS for the VPDL group were not reached. Two-year CR duration was 87.5% in the VPDL group and 50.0% in the ASCT group (P=0.096). Median CR duration was not reached in the VPDL group and 9.8 months in ASCT group.
Toxicity and causes of death
All the patients in both groups experienced grade 4 neutropenia and grade 3 or 4 thrombocytopenia.
Systemic antibiotics were required in 10 out of 11 courses (90.9%) of ASCT and 69.2% in VPDL courses for infection (P=0.085). All the patients in ASCT group experienced grade 3 or 4 stomatitis but 2 patients (7.7%) in VPDL group experienced grade 2 stomatitis. Nausea and vomiting were minimal in VPDL group. No patient in VPDL group experienced acute pancreatitis related to L-asparaginase. Of the 11 patients in the ASCT group, 8 died, 3 of infection (2 pneumonia and 1 varicella-zoster virus related sepsis), 3 of disease progression, 1 of graft versus host disease (GVHD) after salvage allo-SCT and 1 of veno-oc-clusive disease (VOD). Two deaths in the ASCT group were attributed to treatment; one patient died of pneumonia 14 days after ASCT and the other of VOD 1 month after ASCT. Of the 13 patients in the VPDL group, two died, one of sepsis and the other of disease progression.
DISCUSSION
In an overview of the Non-Hodgkin's Lymphoma Classification Project, the EFS rate for T-LBL was 24% at 6 years. 1) In addition, the CR rate has been reported to be only 10%, with a median survival of 12 months. 15) A variety of therapeutic approaches have been attempted for adult LBL due to the relatively high relapse and poor response rates. Conventional NHL protocols with CHOP or CHOP-like regimens have yielded low CR rates, ranging between 53% and 79%. [3] [4] [5] [6] Intensive multiagent chemotherapy analogous to that used in ALL (ALL-type chemotherapy) in patients with B-/T-LBL have resulted in CR rates of 77% to 100% and EFS rates of 45% to 67% suggesting that ALL-type chemotherapy may be effective for T-LBL. 5, [16] [17] [18] The use of high-dose therapy (HDT) and SCT has been attempted to consolidate first remission after standard induction therapy, with 60% to 80% of patients achieving long-term EFS. 5, [7] [8] [9] Although a randomized study comparing chemotherapy alone and chemotherapy consolidated with ASCT was initiated to define the role of SCT in the treatment of LBL, the trial had to be terminated early because of poor accrual. 10) This study failed to show significant survival benefit of ASCT with 2-year OS rate of 57% in ASCT group compared with 53% in patients treated with chemotherapy alone (P=0.71). Two-year relapse-free survival rates in ASCT and chemotherapy alone groups were 50% and 29%, respectively (P=0.065).
Our results showed that chemotherapy alone could produce very good outcomes in patients with T-LBL, with 2-year OS and EFS rates in the VPDL group of 83.9% and 83.1%, respectively.
Six of the 11 patients in the ASCT group attained or sustained CR after ASCT, whereas all those who failed to attain CR died of disease progression or infection. In contrast, 9 of the 13 patients (69.2%) in the VPDL group attained CR and all survived through last follow-up. The results of VPDL chemotherapy compared favorably with those of previously published studies. The regimen known as 'Stanford/NCOG' of modified CHOP chemotherapy incorporating asparaginase, central nervous system prophylaxis and maintenance therapy showed CR rates of 79% to 100% and EFS rates of 23% to 58%. 5, 19, 20, 21) Our results was not inferior to other ALL-type chemotherapy which resulted in CR rates between 77% and 100% and EFS rates of 45% to 67% in patients with B-/T-LBL. 5, [16] [17] [18] We found that our group of ASCT patients had a poorer outcome compared with previous reports. 5, [7] [8] [9] This may be due to different study populations. In most studies, ASCT was performed as consolidation therapy for patients in CR after initial chemotherapy. In contrast, 10 of our 11 ASCT had achieved PR after initial chemotherapy, suggesting that ASCT may have yielded better outcomes if performed on patients in CR only. Also proportion of patients with high or high intermediate age-adjusted IPI was higher in the ASCT group although it was not statistically significant.
Our study has several limitations, including its small sample size and short follow-up period, as well as its inhomogeneous population and diverse regimens of initial chemotherapy in the ASCT group. Nevertheless, our experience with the VPDL regimen in patients with T-LBL is very encouraging, especially considering the potential adverse effects of ASCT, including severe mucositis, infection, VOD and treatment-related mortality. We have shown that VPDL chemotherapy without ASCT effectively induced and sustained remission of T-LBL. This study suggests that VPDL chemotherapy is very effective and can be superior to upfront ASCT in the treatment of T-LBL patients in conclusion. 
